Celldex Therapeutics (CLDX) Net Margin (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Net Margin of 572686.67% for Q1 2026, down 56494624.0% year-over-year from N/an in Q1 2025, and down 532.14% quarter-over-quarter from 90594.21% in Q4 2025.
Celldex Therapeutics (CLDX) Net Margin (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Net Margin history runs 17 years deep, the most recent figure standing at 572686.67% for Q1 2026.
- In Q1 2026, Net Margin fell 56494624.0% year-over-year to 572686.67%; the TTM figure through Mar 2026 stood at 37733.6% (down 3536705.0% YoY), while the FY2025 annual figure was 42819.42%, down 4057013.0% from the prior year.
- Net Margin for Q1 2026 stood at 572686.67%, down from 90594.21% in the prior quarter.
- The five-year high for Net Margin was 1048.32% in Q4 2023, with the low at 572686.67% in Q1 2026.
- The 5-year median for Net Margin is 7160.63% (2022), against an average of 48072.46%.
- The sharpest annual moves came in 2025 and 2026: Net Margin soared 1329034 bps in 2025, then tumbled 56494624 bps in 2026.
- Celldex Therapeutics' Net Margin stood at 1642.1% in 2022, then jumped by 36 bps to 1048.32% in 2023, then plunged by 283 bps to 4010.98% in 2024, then plunged by 2159 bps to 90594.21% in 2025, then slumped by 532 bps to 572686.67% in 2026.
- Business Quant data shows CLDX's Net Margin at 572686.67% in Q1 2026, 90594.21% in Q4 2025, and 8795.07% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | -340,390.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -340,390.91% |
| Mar 31, 2026 | -572,686.67% |
| Dec 31, 2025 | -90,594.21% |
| Jun 30, 2025 | -8,795.07% |
| Mar 31, 2025 | -7,740.43% |
| Dec 31, 2024 | -4,010.98% |
| Sep 30, 2024 | -1,319.99% |
| Jun 30, 2024 | -1,434.83% |
| Mar 31, 2024 | -21,030.77% |
| Dec 31, 2023 | -1,048.32% |
| Sep 30, 2023 | -2,522.08% |
| Jun 30, 2023 | -11,381.34% |
| Mar 31, 2023 | -3,036.30% |
| Dec 31, 2022 | -1,642.10% |
| Sep 30, 2022 | -6,580.84% |
| Jun 30, 2022 | -22,088.34% |
| Mar 31, 2022 | -13,247.13% |
| Dec 31, 2021 | -6,032.34% |
| Sep 30, 2021 | -13,367.32% |
| Jun 30, 2021 | -384.28% |